Trial Profile
A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors BioNTech
- 17 Dec 2021 Status changed from active, no longer recruiting to completed.
- 27 Oct 2021 Planned End Date changed from 30 Oct 2021 to 29 Nov 2021.
- 27 Oct 2021 Planned primary completion date changed from 30 Oct 2021 to 29 Nov 2021.